WuXi Biologics (Cayman) Inc. (WXXWY)

WuXi Biologics Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	8,279	9,670	6,395	9,003	7,096
Short-Term Investments	1,907	340	304.47	1,148	1,272
Trading Asset Securities	523.59	1,234	2,015	975.58	112.47
Cash & Short-Term Investments	10,710	11,243	8,714	11,126	8,481
Cash Growth	-4.75%	29.02%	-21.68%	31.20%	25.67%
Accounts Receivable	5,735	6,184	5,158	3,273	2,371
Other Receivables	639.86	490.64	616.59	908.05	349.37
Receivables	6,374	6,675	5,775	4,181	2,770
Inventory	1,522	1,766	2,281	1,687	1,084
Other Current Assets	4,967	1,514	1,700	2,535	1,870
Total Current Assets	23,573	21,198	18,470	19,530	14,204
Property, Plant & Equipment	28,435	29,939	25,916	19,756	12,870
Long-Term Investments	2,400	2,934	2,709	2,203	1,074
Goodwill	1,530	1,530	1,530	1,530	185.41
Other Intangible Assets	442.37	511.83	548.78	600.65	391.86
Long-Term Accounts Receivable	85.67	165.5	109.17	124.49	87.67
Long-Term Deferred Tax Assets	444.32	235.78	222.57	220.79	80.14
Other Long-Term Assets	66.78	60.69	58.88	68.42	70.35
Total Assets	56,977	56,576	49,564	44,033	28,964
Accounts Payable	747.15	833.27	794.39	617.78	646
Accrued Expenses	825.39	805.04	997.89	852.59	532.15
Current Portion of Long-Term Debt	2,435	576.33	1,321	2,122	767.13
Current Portion of Leases	183.7	154.98	149.06	103.56	60.71
Current Income Taxes Payable	647.66	618.88	773.83	557.73	250.89
Current Unearned Revenue	2,356	3,090	3,379	1,734	664.86
Other Current Liabilities	1,426	1,558	1,903	2,268	1,577
Total Current Liabilities	8,621	7,636	9,319	8,256	4,498
Long-Term Debt	200.9	1,571	1,462	640.51	1,838
Long-Term Leases	2,120	2,259	1,490	1,429	666.51
Long-Term Unearned Revenue	460.47	969.23	949.46	876.73	873.69
Long-Term Deferred Tax Liabilities	97.31	122.54	132.08	124.21	180.89
Other Long-Term Liabilities	-	-	-	-	7.26
Total Liabilities	11,500	12,558	13,351	11,326	8,064
Common Stock	0.23	0.24	0.23	0.24	0.23
Additional Paid-In Capital	-	24,489	22,102	27,044	15,950
Retained Earnings	-	14,978	11,578	7,158	3,769
Treasury Stock	-	-916.92	-	-2,517	-
Comprehensive Income & Other	41,819	1,782	1,367	593.13	845.19
Total Common Equity	41,819	40,332	35,047	32,279	20,564
Minority Interest	3,658	3,686	1,166	427.57	334.95
Shareholders' Equity	45,478	44,018	36,213	32,706	20,899
Total Liabilities & Equity	56,977	56,576	49,564	44,033	28,964
Total Debt	4,940	4,561	4,422	4,295	3,332
Net Cash (Debt)	5,770	6,682	4,293	6,831	5,149
Net Cash Growth	-13.65%	55.66%	-37.16%	32.68%	13.04%
Net Cash Per Share	1.36	1.54	0.98	1.54	1.22
Filing Date Shares Outstanding	4,106	4,223	4,225	4,224	4,085
Total Common Shares Outstanding	4,106	4,223	4,225	4,224	4,085
Working Capital	14,952	13,562	9,151	11,274	9,706
Book Value Per Share	10.19	9.55	8.29	7.64	5.03
Tangible Book Value	39,847	38,290	32,969	30,148	19,987
Tangible Book Value Per Share	9.70	9.07	7.80	7.14	4.89
Land	-	6,195	2,114	2,097	301.16
Machinery	-	7,632	6,029	4,997	2,662
Construction In Progress	-	13,750	15,935	10,873	8,911
Leasehold Improvements	-	3,357	2,581	1,795	1,305
Order Backlog	135,033	146,016	-	86,376	73,930

Updated Sep 20, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.